| Liraglutide: the therapeutic promise from animal models. | |
| | |
MedLine Citation:
|
PMID: 20887299 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIMS: To review the differences between the human glucagon-like peptide-1 (GLP-1) molecule and the analogue liraglutide, and to summarise key data from the liraglutide preclinical study programme showing the therapeutic promise of this new agent. KEY FINDINGS: Liraglutide is a full agonist of the GLP-1 receptor and shares 97% of its amino acid sequence identity with human GLP-1. Unlike human GLP-1, however, liraglutide binds reversibly to serum albumin, and thus has increased resistance to enzymatic degradation and a longer half-life. In preclinical studies, liraglutide demonstrated good glycaemic control, mediated by the glucose-dependent stimulation of insulin and suppression of glucagon secretion and by delayed gastric emptying. Liraglutide also had positive effects on body weight, beta-cell preservation and mass, and cardiac function. CONCLUSIONS: The therapeutic promise of liraglutide is evident from preclinical data. Liraglutide showed the potential to provide good glycaemic control without increasing the risk of hypoglycaemia and, as with exenatide, but not dipeptidyl peptidase-4 inhibitors, to mediate weight loss. Although these benefits have subsequently been studied clinically, beta-cell mass can be directly studied only in animal models. In common with other incretin-based therapies, liraglutide showed the potential to modulate the progressive loss of beta-cell function that drives the continuing deterioration in glycaemic control in patients with type 2 diabetes. Body weight was lowered by a mechanism involving mainly lowered energy intake, but also potentially altered food preference and maintained energy expenditure despite weight loss. |
| | |
Authors:
|
L B Knudsen |
Related Documents
:
|
15853709 - The therapeutic potential of inhibitors of dipeptidyl peptidase iv (dpp iv) and related... 1001849 - Response of gastric inhibitory polypeptide (gip) to test meal in chronic pancreatitis--... 2140609 - Negative allesthesia and decreased endogenous opiate system activity in anorexia nervosa. 9568699 - Mouse pancreatic beta-cells exhibit preserved glucose competence after disruption of th... 16322789 - New ways in which glp-1 can regulate glucose homeostasis. 16644709 - Improvement of glucose tolerance and hepatic insulin sensitivity by oligofructose requi... 14960129 - Spotlight on vardenafil in erectile dysfunction. 21574159 - Impact of endothelial activation on infective and inflammatory complications after card... 15808679 - Xenotransplantation of neonatal porcine islets and sertoli cells into nonimmunosuppress... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: International journal of clinical practice. Supplement Volume: - ISSN: 1368-504X ISO Abbreviation: Int J Clin Pract Suppl Publication Date: 2010 Oct |
Date Detail:
|
Created Date: 2010-10-04 Completed Date: 2011-04-27 Revised Date: 2011-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 9712380 Medline TA: Int J Clin Pract Suppl Country: England |
Other Details:
|
Languages: eng Pagination: 4-11 Citation Subset: IM |
Copyright Information:
|
© 2010 Blackwell Publishing Ltd. |
Affiliation:
|
Department Biology and Pharmacology Mgt, Novo Nordisk A/S, Novo Nordisk Park, DK-2760, Måløv, Denmark. lbkn@novonordisk.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Body Weight / drug effects Diabetes Mellitus, Type 2* / drug therapy, metabolism, physiopathology Dipeptidyl-Peptidase IV Inhibitors / pharmacology Glucagon / metabolism Glucagon-Like Peptide 1 / analogs & derivatives*, metabolism, pharmacology Hemoglobin A, Glycosylated / metabolism Humans Hypoglycemic Agents / pharmacology Insulin / metabolism, therapeutic use Insulin-Secreting Cells / drug effects, metabolism Mice Mice, Obese Peptides / pharmacology Rats Rats, Zucker Receptors, Glucagon / agonists, metabolism Swine Swine, Miniature Venoms / pharmacology |
| Chemical | |
Reg. No./Substance:
|
0/Dipeptidyl-Peptidase IV Inhibitors; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/Peptides; 0/Receptors, Glucagon; 0/Venoms; 0/glucagon-like peptide receptor; 0/liraglutide; 11061-68-0/Insulin; 141732-76-5/exenatide; 89750-14-1/Glucagon-Like Peptide 1; 9007-92-5/Glucagon |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Valid and precise measurement.
Next Document: Early clinical studies with liraglutide.